Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) shares were up 9.2% during mid-day trading on Thursday . The company traded as high as $15.72 and last traded at $15.14. Approximately 36,442 shares traded hands during trading, a decline of 56% from the average daily volume of 82,304 shares. The stock had previously closed at $13.86.
Gyre Therapeutics Stock Performance
The firm’s 50-day moving average price is $17.68. The firm has a market cap of $1.21 billion, a PE ratio of -0.67 and a beta of 2.13.
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
- Five stocks we like better than Gyre Therapeutics
- What Does Downgrade Mean in Investing?
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- How to invest in blue chip stocks
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
